ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has taken remedial actions after it failed to inform the Hong Kong bourse regarding the extension of the subscription of certain wealth management products, a Tuesday Hong Kong bourse filing said.
The issue arose as the company considered an extension in the subscription as an immaterial modification instead of a new subscription under the bourse's listing rules.
The firm conducted a detailed review of its wealth management product subscription, pledged to comply with information disclosure requirements, and decided to provide training to the relevant individuals among other measures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.